Transient ischaemic attack

When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 22 Nov 2024
Last updated: 21 Aug 2024

Summary

Definition

History and exam

Key diagnostic factors

  • sudden onset and brief duration of symptoms (minutes)
  • patient/witness report of focal neurological deficit
Full details

Other diagnostic factors

  • unilateral weakness or paralysis
  • dysphasia
  • ataxia, vertigo, or loss of balance
  • sudden transient loss of vision in one eye (amaurosis fugax)
  • homonymous hemianopia
  • diplopia
  • risk factors
Full details

Risk factors

  • atrial fibrillation
  • valvular disease
  • carotid stenosis
  • intracranial stenosis
  • congestive heart failure
  • hypertension
  • hyperlipidaemia
  • diabetes mellitus
  • cigarette smoking
  • alcohol-use disorder
  • advanced age
  • patent foramen ovale (PFO)
  • inactivity
  • obesity
  • hypercoagulability
Full details

Diagnostic investigations

1st investigations to order

  • blood glucose
  • full blood count and platelet count
  • prothrombin time, INR, partial thromboplastin time
  • fasting lipid profile
  • serum electrolytes
  • ECG
Full details

Investigations to consider

  • CT scan
Full details

Treatment algorithm

INITIAL

suspected transient ischaemic attack

ACUTE

confirmed transient ischaemic attack

Contributors

Expert advisers

Matthew Jones, MD, FRCP

Consultant Neurologist

Manchester Centre for Clinical Neurosciences

Northern Care Alliance

Honorary Senior Lecturer

University of Manchester

Manchester

UK

Disclosures

MJ is the chair of the Association of British Neurologists Education Committee (unpaid position). MJ is a faculty member of a MRCP revision course. MJ has received honoraria from Eisai for educational talks.

Rachael Power, MBChB, MRCP

Neurology Registrar

Manchester Centre for Clinical Neurosciences

Manchester

UK

Disclosures

RP has been sponsored by Novartis to attend the International Headache Conference.

Acknowledgements

BMJ Best Practice would like to gratefully acknowledge the previous team of expert contributors, whose work is retained in parts of the content:

Jennifer Simpson, MD

Associate Assistant Professor

Department of Neurology

University of Colorado School of Medicine

Denver

CO

Disclosures: JS is a site investigator for the POINT trial.

Ethan Cumbler, MD

Associate Professor

Section of Hospital Medicine

Department of Internal Medicine

Division of Medicine

University of Colorado School of Medicine

Denver

CO

Disclosures: EC declares that he has no competing interests.

Peer reviewers

Kayvan Khadjooi, MD, FRCP, PGCertMedEd

Consultant in Stroke Medicine

Addenbrooke’s Hospital

Associate Lecturer

School of Clinical Medicine

University of Cambridge

Cambridge

UK

Disclosures

KK has received travel grants for conferences/speaker honoraria from Bayer, Boehringer, Daiichi-Sankyo, Pfizer, and Shire.

Editors

Helena Delgado-Cohen

Section Editor, BMJ Best Practice

Disclosures

HDC declares that she has no competing interests.

Tannaz Aliabadi-Oglesby

Lead Section Editor, BMJ Best Practice

Disclosures

TAO declares that she has no competing interests.

Susan Mayor

Lead Section Editor, BMJ Best Practice

Disclosures

SM works as a freelance medical journalist and editor, video editorial director and presenter, and communications trainer. In this capacity, she has been paid, and continues to be paid, by a wide range of organisations for providing these skills on a professional basis. These include: NHS organisations, including the National Institute for Health and Care Excellence, NHS Choices, NHS Kidney Care, and others; publishers and medical education companies, including the BMJ Group, the Lancet group, Medscape, and others; professional organisations, including the British Thoracic Oncology Group, the European Society for Medical Oncology, the National Confidential Enquiry into Patient Outcome and Death, and others; charities and patients’ organisations, including the Roy Castle Lung Cancer Foundation and others; pharmaceutical companies, including Bayer, Boehringer Ingelheim, Novartis, and others; and communications agencies, including Publicis, Red Healthcare and others. She has no stock options or shares in any pharmaceutical or healthcare companies; however, she invests in a personal pension, which may invest in these types of companies. She is managing director of Susan Mayor Limited, the company name under which she provides medical writing and communications services.

Julie Costello

Comorbidities Editor, BMJ Best Practice

Disclosures

JC declares that she has no competing interests.

Adam Mitchell

Drug Editor, BMJ Best Practice

Disclosures

AM declares that he has no competing interests.

  • Differentials

    • Stroke
    • Hypoglycaemia
    • Seizure with post-seizure (Todd's) paralysis
    More Differentials
  • Guidelines

    • Hypertension in adults: diagnosis and management
    • Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
    More Guidelines
  • Calculators

    NIH Stroke Score

    More Calculators
  • Videos

    How to perform an ECG animated demonstration

    Venepuncture and phlebotomy animated demonstration

    More videos
  • Patient information

    Transient ischaemic attack (mini stroke)

    Stroke: treatment

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer